Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.4, 1999-04, pp. : 477-480
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Two patents claiming the use of structurally distinct p38 (mitogen-activated protein, MAP) kinase inhibitors are compared. One claims bisarylpyrazole derivatives and provides effective anti-inflammatory agents. The second claims the use of bisarylureas, which provide a novel non-azole template, as p38 inhibitors.
Related content
The Discovery of Novel Chemotypes of p38 Kinase Inhibitors
Current Topics in Medicinal Chemistry, Vol. 5, Iss. 10, 2005-09 ,pp. :
Access to resources
Recommend
By Hanson G.J.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 7, 1997-07 ,pp. :
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 1, 2000-01 ,pp. :
Allosteric p38 kinase inhibitors
By Norman Peter
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 10, 2006-10 ,pp. :